文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Familial hypercholesterolemia: The Italian Atherosclerosis Society Network (LIPIGEN).

作者信息

Averna Maurizio, Cefalù Angelo B, Casula Manuela, Noto Davide, Arca Marcello, Bertolini Stefano, Calandra Sebastiano, Catapano Alberico L, Tarugi Patrizia

机构信息

Dipartimento Biomedico di Medicina Interna e Specialistica (Di.Bi.M.I.S.), University of Palermo, Palermo, Italy.

Dipartimento Biomedico di Medicina Interna e Specialistica (Di.Bi.M.I.S.), University of Palermo, Palermo, Italy.

出版信息

Atheroscler Suppl. 2017 Oct;29:11-16. doi: 10.1016/j.atherosclerosissup.2017.07.001.


DOI:10.1016/j.atherosclerosissup.2017.07.001
PMID:28965615
Abstract

BACKGROUND AND AIMS: Primary dyslipidemias are a heterogeneous group of disorders characterized by abnormal levels of circulating lipoproteins. Among them, familial hypercholesterolemia is the most common lipid disorder that predisposes for premature cardiovascular disease. We set up an Italian nationwide network aimed at facilitating the clinical and genetic diagnosis of genetic dyslipidemias named LIPIGEN (LIpid TransPort Disorders Italian GEnetic Network). METHODS: Observational, multicenter, retrospective and prospective study involving about 40 Italian clinical centers. Genetic testing of the appropriate candidate genes at one of six molecular diagnostic laboratories serving as nationwide DNA diagnostic centers. RESULTS AND CONCLUSIONS: From 2012 to October 2016, available biochemical and clinical information of 3480 subjects with familial hypercholesterolemia identified according to the Dutch Lipid Clinic Network (DLCN) score were included in the database and genetic analysis was performed in 97.8% of subjects, with a mutation detection rate of 92.0% in patients with DLCN score ≥6. The establishment of the LIPIGEN network will have important effects on clinical management and it will improve the overall identification and treatment of primary dyslipidemias in Italy.

摘要

相似文献

[1]
Familial hypercholesterolemia: The Italian Atherosclerosis Society Network (LIPIGEN).

Atheroscler Suppl. 2017-10

[2]
Spectrum of mutations in Italian patients with familial hypercholesterolemia: New results from the LIPIGEN study.

Atheroscler Suppl. 2017-10

[3]
Evaluation of the performance of Dutch Lipid Clinic Network score in an Italian FH population: The LIPIGEN study.

Atherosclerosis. 2018-10

[4]
Detection of familial hypercholesterolemia in patients from a general practice database.

Atheroscler Suppl. 2017-10

[5]
The study of familial hypercholesterolemia in Italy: A narrative review.

Atheroscler Suppl. 2017-10

[6]
Causative mutations and premature cardiovascular disease in patients with heterozygous familial hypercholesterolaemia.

Eur J Prev Cardiol. 2017-7

[7]
Landmark position paper on paediatric familial hypercholesterolaemia from the EAS Consensus Panel.

Atherosclerosis. 2015-9

[8]
Evaluation of clinical and laboratory parameters used in the identification of index cases for genetic screening of familial hypercholesterolemia in Brazil.

Atherosclerosis. 2017-6-22

[9]
What is the actual epidemiology of familial hypercholesterolemia in Italy? Evidence from a National Primary Care Database.

Int J Cardiol. 2016-11-15

[10]
Efficacy of clinical diagnostic criteria for familial hypercholesterolemia genetic testing in Poland.

Atherosclerosis. 2016-6

引用本文的文献

[1]
Evaluation of glycemic status and subclinical atherosclerosis in familial hypercholesterolemia subjects with or without LDL receptor mutation.

Cardiovasc Diabetol. 2025-3-20

[2]
An 8-SNP LDL Cholesterol Polygenic Score: Associations with Cardiovascular Risk Traits, Familial Hypercholesterolemia Phenotype, and Premature Coronary Heart Disease in Central Romania.

Int J Mol Sci. 2024-9-18

[3]
Women and lipoprotein apheresis: another side of gender medicine.

Endocrine. 2024-12

[4]
Simplified Criteria for Identification of Familial Hypercholesterolemia in Children: Application in Real Life.

J Cardiovasc Dev Dis. 2024-4-17

[5]
Double mutation in genes associated to FH and diabetes.

Acta Diabetol. 2024-5

[6]
The impact of SLCO1B1 rs4149056 on LDL-C target achievement after lipid lowering therapy optimization in men and women with familial hypercholesterolemia.

Front Endocrinol (Lausanne). 2024

[7]
Clinical Approach in the Management of Paediatric Patients with Familial Hypercholesterolemia: A National Survey Conducted by the LIPIGEN Paediatric Group.

Nutrients. 2023-8-5

[8]
Painful and recurring injection site reaction to alirocumab and evolocumab in a young woman with familial hypercholesterolemia and effective therapeutic alternative based on inclisiran: a case report.

Front Cardiovasc Med. 2023-6-23

[9]
Lipoprotein(a) Genotype Influences the Clinical Diagnosis of Familial Hypercholesterolemia.

J Am Heart Assoc. 2023-5-16

[10]
Genetic Heterogeneity of Familial Hypercholesterolemia: Repercussions for Molecular Diagnosis.

Int J Mol Sci. 2023-2-6

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索